Comparative Pharmacology
Head-to-head clinical analysis: EXTENDED PHENYTOIN SODIUM versus QUDEXY XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXTENDED PHENYTOIN SODIUM versus QUDEXY XR.
EXTENDED PHENYTOIN SODIUM vs QUDEXY XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenytoin stabilizes neuronal membranes by promoting sodium channel inactivation, reducing repetitive firing of action potentials, and decreasing synaptic transmission.
Stabilizes neuronal membranes and inhibits repetitive firing of action potentials via blockade of voltage-gated sodium channels; also enhances GABAergic activity and inhibits glutamate release.
Oral: 100 mg three times daily; intravenous: 10-20 mg/kg loading dose at a maximum rate of 50 mg/min, then 100 mg every 6-8 hours maintenance.
Initial dose 25 mg orally twice daily; titrate by 25-50 mg/day every 1-2 weeks to target dose of 200-400 mg/day in two divided doses. Maximum 400 mg/day.
None Documented
None Documented
22–32 hours (mean 24 hours) in adults, dose-dependent due to saturable metabolism; may exceed 60 hours at high concentrations.
Terminal elimination half-life is approximately 70-90 hours after multiple dosing, supporting twice-daily dosing; requires slow titration to steady state (2-3 weeks).
Primarily hepatic metabolism (CYP2C9/CYP2C19), with <5% excreted unchanged renally. Fecal excretion accounts for minor elimination.
Renal: approximately 70% as unchanged drug; fecal: approximately 20%; biliary: minor (<5%).
Category D/X
Category C
Anticonvulsant
Anticonvulsant